Supplementary Fig. 1

1. DBM1285 [cyclopropyl-{4-[4-(4-fluorophenyl)-2-piperidin-4-yl-thiazol-5-yl]pyrimidin-2-yl}amine] suppresses tumor necrosis factor-a production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway, Kang JS, Kim HM, Choi IY, Han SB, Yoon YD, Lee H, Park KH, Cho IG, Lee CW, Lee K, Lee KH and Park SK, Journal of Pharmacology and Experimental Therapeutics Supplementary Fig. 1 A B 100 120 80 100 80 60 cpm (x 103) cpm (x 103) 60 40 40 20 20 0 0 UN VH 0.001 0.01 0.1 1 10 UN VH 0.001 0.01 0.1 1 10 ConA (1 mg/ml) + DBM1285 (mM) LPS (1 mg/ml) + DBM1285 (mM) Effect of DBM1285 on ConA- or LPS-induced proliferation in mouse splenocytes. Total splenocytes were prepared and cells were plated at 1 X 106 cells/ml. Vehicle (VH, DMSO) or indicated concentrations of DBM1285 (0.001, 0.01, 0.1, 1 or 10 mM) was pretreated for 1 h before being incubated with (A) ConA (1 mg/ml) or (B) LPS (1 mg/ml) for 72 h. Cells were pulsed with 1 mCi/well of [3H]-thymidine (113 Ci/nmol; NEN, Boston, MA, USA) for the last 18 h and harvested with an automated cell harvester (Inotech, Dottikon, Switzerland). The amount of incorporated [3H]–thymidine was measured using a Wallac Microbeta scintillation counter (Wallac, Turku, Finland). Each column shows the mean ± S.D. of triplicate determinations.